Shares of BELLUS Health Inc. (NASDAQ:BLU) have been assigned a consensus recommendation of “Buy” from the seven research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $11.75.
Several equities analysts recently weighed in on BLU shares. HC Wainwright reiterated a “buy” rating and set a $14.00 target price (up from $10.00) on shares of BELLUS Health in a research report on Tuesday, September 14th. Zacks Investment Research raised BELLUS Health from a “sell” rating to a “hold” rating in a research report on Thursday, August 12th. Bloom Burton reaffirmed a “buy” rating on shares of BELLUS Health in a research note on Friday, August 13th. Finally, BTIG Research reiterated a “buy” rating and issued a $13.00 target price on shares of BELLUS Health in a report on Sunday.
Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC purchased a new position in shares of BELLUS Health in the first quarter valued at $146,000. Rockefeller Capital Management L.P. purchased a new stake in BELLUS Health during the 2nd quarter valued at $616,000. Laurion Capital Management LP raised its holdings in BELLUS Health by 2,813.6% in the 1st quarter. Laurion Capital Management LP now owns 2,913,619 shares of the company’s stock worth $11,188,000 after purchasing an additional 2,813,619 shares during the period. D.A. Davidson & CO. grew its position in shares of BELLUS Health by 348.6% during the first quarter. D.A. Davidson & CO. now owns 170,900 shares of the company’s stock valued at $656,000 after purchasing an additional 132,800 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in shares of BELLUS Health by 1,137.7% during the second quarter. Deutsche Bank AG now owns 97,782 shares of the company’s stock valued at $304,000 after buying an additional 89,882 shares during the period. 61.12% of the stock is currently owned by hedge funds and other institutional investors.
BELLUS Health (NASDAQ:BLU) last announced its earnings results on Tuesday, August 10th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). BELLUS Health had a negative return on equity of 36.47% and a negative net margin of 311,879.97%. Research analysts anticipate that BELLUS Health will post -0.85 EPS for the current fiscal year.
BELLUS Health Company Profile
BELLUS Health, Inc is a biopharmaceutical development company which engages in the research and development of novel therapeutics for the treatment of chronic cough and other hypersensitisation disorders. Its product, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch.
Read More: What is a growth and income fund?
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.